Merrimack Pharma Raises $60 Million

Merrimack Pharmaceuticals Inc., a Cambridge, Mass.-based biotechnology company focused on the discovery and development of novel treatments for autoimmune disease and cancer, has raised $60 million in a series F private equity financing.Existing and new investors participated in the financing including Credit Suisse First Boston Next Fund Inc., Crocker Ventures, HNI Holdings Ltd., funds advised by Noonday Asset Management LP, TPG-Axon Capital, and WT Investment Advisors Fund LP. www.merrimackpharma.com